Type 2 Diabetes study (S17GMA10)

Update: This clinical study has now finished. Thank you to everyone who participated.

This clinical study investigates an experimental drug called glutazumab in people with type 2 diabetes.

Glutazumab is being developed for the treatment of type 2 diabetes, which is a metabolic disorder (metabolism is the process the body uses to get or make energy from food). In type 2 diabetes the body’s regulation of insulin level does not work properly. Insulin is a hormone produced in the pancreas that is released in response to increased blood sugar levels (such as occurs after a meal), and it helps the body’s cells break down and store glucose. In type 2 diabetes, non-response to insulin (insulin resistance) and/or lack of insulin production leads to high blood sugar levels. Glutazumab is designed to assist the body in producing insulin.

The purpose of this clinical study of glutazumab is to determine the safety and tolerability of glutazumab when given in repeated escalating (increasing) doses as subcutaneous injections (injections under the skin) in people with type 2 diabetes. The researchers will also study the effectiveness of glutazumab in controlling your diabetes, and identify an appropriate dose of glutazumab for future studies.

This clinical study is no longer recruiting patients and is now complete.

Not required

Weekly visits for 10 to 13 weeks

* have type 2 diabetes for over 6 months
* your diabetes is controlled with diet or exercise alone or with 1 or 2 medicines (oral hypoglycaemics)
* are able to perform self blood glucose monitoring.

When enquiring about this clinical study please quote the study code above